Aquestive Therapeutics (AQST) Non-Current Debt (2017 - 2025)
Historic Non-Current Debt for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $29.9 million.
- Aquestive Therapeutics' Non-Current Debt fell 420.12% to $29.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.9 million, marking a year-over-year decrease of 420.12%. This contributed to the annual value of $32.5 million for FY2024, which is 1814.74% up from last year.
- As of Q3 2025, Aquestive Therapeutics' Non-Current Debt stood at $29.9 million, which was down 420.12% from $31.8 million recorded in Q2 2025.
- Aquestive Therapeutics' Non-Current Debt's 5-year high stood at $51.6 million during Q4 2021, with a 5-year trough of $20.8 million in Q2 2023.
- In the last 5 years, Aquestive Therapeutics' Non-Current Debt had a median value of $32.7 million in 2021 and averaged $33.8 million.
- As far as peak fluctuations go, Aquestive Therapeutics' Non-Current Debt surged by 5016.75% in 2021, and later crashed by 5253.19% in 2023.
- Aquestive Therapeutics' Non-Current Debt (Quarter) stood at $51.6 million in 2021, then plummeted by 35.12% to $33.4 million in 2022, then decreased by 17.76% to $27.5 million in 2023, then rose by 18.15% to $32.5 million in 2024, then fell by 7.88% to $29.9 million in 2025.
- Its Non-Current Debt was $29.9 million in Q3 2025, compared to $31.8 million in Q2 2025 and $33.7 million in Q1 2025.